Cargando…
Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
• Older patients are still underrepresented in randomized controlled clinical trials. • Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit. • Older patients experience more side effects, than their younger counterparts. • Prospective “real-world” data is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846923/ https://www.ncbi.nlm.nih.gov/pubmed/33553556 http://dx.doi.org/10.1016/j.gore.2021.100710 |